RCMNY
VKTX icon

Rubric Capital Management (New York)’s Viking Therapeutics VKTX Stock Holding History

Rubric Capital Management (New York)’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-500,000
Closed -$3.44M – 60
2019
Q3 		$3.44M Buy
+500,000
New +$3.71M 0.32% 50

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Rubric Capital Management (New York)'s VKTX Position: Q4 2019 in Review

Rubric Capital Management (New York) sold out of Viking Therapeutics (VKTX) in Q4 2019, closing a stake of 660,000 shares — an estimated $4.54M sold.

Rubric Capital Management (New York) first reported a position in VKTX in Q1 2019 and held it in 3 quarters. The position peaked at $8.05M in Q1 2019. 143 funds tracked by Wall St. Rank hold VKTX as of Q4 2019.

  • Rubric Capital Management (New York) reported no remaining Viking Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 660,000 Viking Therapeutics shares in Q4 2019, an estimated $4.54M.
  • Rubric Capital Management (New York) first reported a position in Viking Therapeutics in Q1 2019 and held it in 3 quarters.
  • Rubric Capital Management (New York)'s Viking Therapeutics position peaked at $8.05M in Q1 2019.
  • 143 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2019.

Based on Rubric Capital Management (New York)'s 13F filing for Q4 2019, filed 14 Feb 2020.